Specific activity | Screening | Baseline/ randomisation | Intervention (0–3 weeks postrandomisation) | 6 weeks±1 week | 3 months±1 week | 6 months±1 weeks | 12 months±1 weeks |
Check eligibility of potential participant | X | ||||||
Provide patient information sheet | X | ||||||
Take informed consent | X | ||||||
Baseline clinical data collection | X | ||||||
Randomisation | X | ||||||
VAT-PD or IPC | X | ||||||
VAS scores for dyspnoea and chest pain | X | X | X | X | X | X | |
EQ-5D and EORTC QLQC30 | X | X | X | X | X | X | |
Review/reporting of patient AEs/SAEs | X | X | X | X | X | X | |
Qualitative interviews | X | ||||||
Clinical follow-up data | X | X | X | X | |||
Health service and resource use data | X | X | X | X | X |
AEs, adverse events; EORTC, European Organisation for Research and Treatment of Cancer Quality Life Questionnaire; EQ, EuroQoL; IPC, indwelling pleural catheter; SAEs, serious adverse events; VAS, visual analogue scale; VAT-PD, video-assisted thoracoscopic partial pleurectomy/decortication.